Watch RNXT. Know when insiders buy.
One email the day a filing lands. Free.
RNXT
RenovoRx, Inc.
1.52
−0.13 −8.13%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $68.8MP/E —DIV YIELD —FCF YIELD -17.34%REV TTM $2MNET INCOME −$12.3MNET CASH —52W 0.73 – 2.52SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $909K | +115.4% | 84.3% | −$3.3M | −$2.9M | — | -0.06 | −$2.9M | $71K | −$2.9M | Aug 13 |
| Q1 2026 · Mar 31 | $563K | +185.8% | 85.1% | −$3.5M | −$3.5M | — | -0.09 | −$3.7M | $0 | −$3.7M | Aug 13 |
| Q4 2025 · Dec 31derived | $238K | — | 88.2% | −$3.5M | −$2.9M | — | -0.08 | −$3M | $0 | −$3M | Mar 30 |
| Q3 2025 · Sep 30 | $266K | — | 80.1% | −$3.2M | −$2.9M | — | -0.08 | −$2.3M | $0 | −$2.3M | Nov 13 |
| Q2 2025 · Jun 30 | $422K | — | 64.0% | −$2.7M | −$2.9M | — | -0.08 | −$2.3M | $0 | −$2.3M | Aug 13 |
| Q1 2025 · Mar 31 | $197K | — | 52.3% | −$3.1M | −$2.4M | — | -0.08 | −$3.4M | $2K | −$3.4M | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$2.6M | −$2.9M | — | -0.12 | −$2.4M | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$2.8M | −$2.5M | — | -0.10 | −$2.2M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$3M | −$2.4M | — | -0.10 | −$2.3M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$2.5M | −$1.1M | — | -0.07 | −$2.2M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.8M | −$3.2M | — | -0.30 | −$2.1M | — | — | Apr 1 |
| Q3 2023 · Sep 30 | — | — | — | −$3M | −$1.4M | — | -0.13 | −$2.7M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.1M | 70.9% | −$12.5M | −$11.2M | -994.5% | -0.32 | −$11M | $2K | −$11M | — | — |
| FY2024 · to Dec 31 | $43K | 100.0% | −$11M | −$8.8M | -20497.7% | -0.40 | −$9.1M | $12K | −$9.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$11.4M | −$10.2M | — | -0.99 | −$10.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$9.9M | −$9.9M | — | -1.09 | −$8.8M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$5.7M | −$6.3M | — | -1.21 | −$5.9M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$3.2M | −$3.8M | — | -1.72 | −$3.5M | — | — | — | — |
Every number comes from RenovoRx, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.